Sangamo Therapeutics Inc.

Company Overview

Business Model: SANGAMO THERAPEUTICS, INC. is a genomic medicine company focused on translating scientific discoveries into medicines for serious neurological diseases. The company's core value proposition lies in its proprietary zinc finger epigenetic regulators and its capsid engineering platform, which aims to enhance delivery of therapies to neurological targets. Revenue generation primarily stems from collaboration agreements, including upfront license fees, reimbursements for research services, and milestone achievements, as well as research grants.

Market Position: SANGAMO THERAPEUTICS, INC. is a leader in the research and development of gene therapies, cell therapies, and genome engineering therapies utilizing zinc finger DNA-binding proteins. Key competitive advantages include its differentiated and versatile zinc finger technology platform and its proprietary adeno-associated virus (AAV) capsid engineering platform, SIFTER. The STAC-BBB capsid variant, a product of this platform, has demonstrated the ability to cross the blood-brain barrier in preclinical studies, offering a potential advantage in neurological disease treatment. The company operates in a highly competitive biotechnology and genomic medicine landscape.

Recent Strategic Developments:

• Strategic Reprioritization: In 2023, SANGAMO THERAPEUTICS, INC. underwent a strategic transformation to become a neurology-focused genomic medicine company, concentrating efforts on epigenetic regulation therapies for neurological diseases and novel engineered AAV capsid delivery technology.
• ST-503 (Small Fiber Neuropathy): The U.S. Food and Drug Administration (FDA) cleared the Investigational New Drug (IND) application for ST-503 in November 2024, an epigenetic regulator for intractable pain due to small fiber neuropathy. The Phase 1/2 STAND study has commenced patient recruitment and enrollment, and ST-503 received FDA Fast Track Designation in December 2025.
• Isaralgagene civaparvovec (Fabry Disease): The registrational Phase 1/2 STAAR clinical study for this wholly owned gene therapy product candidate has been completed. SANGAMO THERAPEUTICS, INC. initiated a rolling submission of a Biologics License Application (BLA) to the FDA in December 2025, seeking Accelerated Approval based on the mean annualized estimated glomerular filtration rate (eGFR) slope at 52 weeks. Detailed positive topline results from the STAAR study were presented in February 2026, demonstrating potential as a one-time, well-tolerated, and durable gene therapy.
• Giroctocogene fitelparvovec (Hemophilia A): SANGAMO THERAPEUTICS, INC. regained development and commercialization rights to this gene therapy product candidate from Pfizer Inc. in April 2025, following Pfizer Inc.'s termination of their collaboration agreement. The Phase 3 AFFINE trial achieved its primary objective of non-inferiority and superiority in reducing annualized bleeding rate.
• STAC-BBB Capsid: This proprietary engineered neurotropic AAV capsid variant has shown the ability to cross the blood-brain barrier in nonhuman primates and mice, mediating robust transduction and epigenetic repression in the central nervous system. It is the subject of license agreements with Genentech, Inc., Astellas Gene Therapies, Inc., and Eli Lilly and Company.
• Modular Integrase Platform (MINT): The company is developing this next-generation protein-guided genome editing method designed to integrate large DNA sequences into the genome without double-stranded breaks. Updated data demonstrating high-efficiency transgene integration in T cells was presented in May 2025.
• Collaborations: SANGAMO THERAPEUTICS, INC. entered into new license agreements with Genentech, Inc. (August 2024, $50.0 million upfront and milestone), Astellas Gene Therapies, Inc. (December 2024, $20.0 million upfront), and Eli Lilly and Company (April 2025, $18.0 million upfront) for its STAC-BBB capsid and/or zinc finger repressors. Previous collaboration agreements with Biogen and Novartis terminated in June 2023, and with Kite expired in April 2024.

Geographic Footprint: SANGAMO THERAPEUTICS, INC. primarily operates in the United States, with its headquarters in Richmond, California, and an additional facility in Brisbane, California. It also maintains operations in the United Kingdom. All revenues for the years ended December 31, 2025, and 2024, were generated and earned in the United States.

Financial Performance

Revenue Analysis

Profitability Metrics:

• Operating Margin: -306.5%
• Net Margin: -310.8%

Investment in Growth:

• R&D Expenditure: $112.7 million (284.9% of revenue)
• Capital Expenditures: $0.1 million

Business Segment Analysis

SANGAMO THERAPEUTICS, INC. operates as a single reportable segment. Management reviews operating results and assets at a consolidated entity level for resource allocation and financial performance evaluation.

Core Neurology Programs

Financial Performance:

• Wholly owned preclinical programs and early research: $29.5 million (-39.8% YoY)
• Key Growth Drivers: Continued investment in epigenetic regulation therapies and novel engineered AAV capsids for neurological targets.

Product Portfolio:

• ST-503 (Chronic Neuropathic Pain): An investigational epigenetic regulator for intractable pain due to small fiber neuropathy (SFN). It utilizes an AAV vector carrying an engineered zinc finger repressor (ZFR) to specifically target the SCN9A gene, which encodes the Nav1.7 sodium channel critical for pain signaling. The Phase 1/2 STAND study is underway, assessing safety and efficacy.
• ST-506 (Prion Disease): An investigational epigenetic regulator for prion disease, a fatal neurodegenerative condition. This program leverages ZFRs targeting the PRNP gene, delivered by the STAC-BBB neurotropic AAV capsid. Preclinical data demonstrated significant survival extension in mouse models and sustained brain delivery and prion reduction in nonhuman primates.
• STAC-BBB Capsid: A proprietary engineered neurotropic AAV capsid variant that has demonstrated the ability to cross the blood-brain barrier in nonhuman primates and mice, mediating robust transduction and targeted epigenetic repression throughout the brain and spinal cord after intravenous administration.
• Modular Integrase Platform (MINT): A versatile, protein-guided genome editing method designed to integrate large sequences of DNA into the genome, avoiding double-stranded DNA breaks. Preclinical data has shown high-efficiency transgene integration in T cells.

Market Dynamics:

• SFN: Affects an estimated 180,000 patients in the U.S., with a high unmet medical need due to the lack of long-lasting or curative therapies.
• Prion Disease: Approximately 1,500 new cases are identified annually in the United States, Europe, and Japan, representing a fatal and incurable neurodegenerative disease.

Other Clinical Programs

Financial Performance:

• Fabry disease program: $57.8 million (+222.9% YoY)
• Key Growth Drivers: Advancement of isaralgagene civaparvovec towards regulatory approval and potential commercialization. Regaining rights to giroctocogene fitelparvovec.

Product Portfolio:

• Isaralgagene civaparvovec (ST-920) for Fabry Disease: A wholly owned gene therapy product candidate for this rare inherited metabolic disease. The completed Phase 1/2 STAAR study showed positive mean eGFR slopes at 52 and 104 weeks, indicating improved renal function, stable cardiac function, and sustained alpha-galactosidase A activity. All 18 patients on Enzyme Replacement Therapy (ERT) were able to safely withdraw from ERT. The product has received Orphan Drug, Fast Track, and RMAT designations from the FDA, and Orphan Medicinal Product designation and PRIME eligibility from the European Medicines Agency (EMA).
• Giroctocogene fitelparvovec (SB-525) for Hemophilia A: A gene therapy product candidate for moderately severe to severe hemophilia A. The Phase 3 AFFINE trial demonstrated a statistically significant reduction in mean total and treated annualized bleeding rates compared to prophylaxis, with endogenous Factor VIII expression in the mild to normal range for most participants.

Market Dynamics:

• Fabry Disease: A rare inherited metabolic disease with a significant need for effective, durable treatment options.
• Hemophilia A: A genetic bleeding disorder where giroctocogene fitelparvovec aims to provide sustained Factor VIII expression.

Capital Allocation Strategy

Balance Sheet Position:

• Cash and Equivalents: $20.9 million (as of December 31, 2025)
• Total Lease Liabilities: $26.8 million (as of December 31, 2025)
• Net Cash Position: $(5.8) million (as of December 31, 2025)
• Debt Maturity Profile: Lease liabilities include $2.7 million in 2026, $12.4 million in 2027, $7.5 million in 2028, $4.4 million in 2029, $2.2 million in 2030, and $1.5 million thereafter. The weighted-average remaining lease term is 4.3 years.

Cash Flow Generation:

• Operating Cash Flow: $(97.2) million
• Free Cash Flow: $(97.3) million

Operational Excellence

Production & Service Model: SANGAMO THERAPEUTICS, INC. is substantially reliant on external partners, specifically Contract Manufacturing Organizations (CMOs), for the manufacture of preclinical and clinical supply for its neurology portfolio. The company maintains in-house analytical and process development capabilities. It utilizes both a commercial-scale insect-based baculovirus manufacturing platform and a clinical-scale HEK293 mammalian platform for AAV vector production.

Supply Chain Architecture: Key Suppliers & Partners:

• Contract Manufacturing Organizations (CMOs): Responsible for producing AAV product candidates in compliance with FDA and EMA cGMP regulations.
• Single Suppliers: Certain critical materials and key components are sourced from single suppliers, which could pose risks of delays if supply is interrupted.

Facility Network:

• Manufacturing: Relies on CMOs.
• Research & Development: Corporate headquarters in Richmond, California (approximately 59,485 square feet of research and office space, lease expires August 2031; approximately 7,700 square feet of office space, lease expires August 2026). Also leases approximately 103,089 square feet of office and research and development laboratory facility in Brisbane, California (lease expires May 2029).
• Former Facilities: The cell therapy manufacturing facility and research labs in Valbonne, France, were closed in March 2024 as part of a restructuring.

Market Access & Customer Relationships

Go-to-Market Strategy: Distribution Channels:

• Channel Partners: SANGAMO THERAPEUTICS, INC. leverages strategic collaborations with biopharmaceutical companies to utilize their therapeutic and clinical expertise and commercial resources for product development and potential commercialization.

Customer Portfolio: Enterprise Customers:

• Strategic Partnerships: Key partners include Genentech, Inc., Astellas Gene Therapies, Inc., Eli Lilly and Company, Alexion Pharmaceuticals, Inc., Takeda Pharmaceutical Company Limited, Corteva AgriScience, Sigma-Aldrich Corporation, and Open Monoclonal Technology, Inc. (now Ligand Pharmaceuticals Incorporated).
• Customer Concentration: In 2025, primary revenue contributors were Eli Lilly and Company (47%), Pfizer Inc. (28%), and Astellas Gene Therapies, Inc. (19%). In 2024, Genentech, Inc. accounted for 87% of revenue, and Astellas Gene Therapies, Inc. for 11%. Accounts receivable concentration as of December 31, 2025, showed Sigma-Aldrich Corporation at 70%.

Geographic Revenue Distribution:

• United States: 100% of total revenue for the years ended December 31, 2025, and 2024.

Competitive Intelligence

Market Structure & Dynamics

Industry Characteristics: The biotechnology and genomic medicine industries are highly competitive and characterized by rapid technological change. The novelty of genomic medicine technologies introduces significant uncertainty regarding the timing and costs of development and regulatory approval. Public perception and heightened regulatory scrutiny of genetically modified products are also material factors.

Competitive Positioning Matrix:

Direct Competitors

Primary Competitors:

• Protein pharmaceuticals: F. Hoffman-LaRoche Ltd., Protalix Biotherapeutics, Inc., Sanofi S.A., and other biopharmaceutical firms.
• Gene therapy companies: BioMarin Pharmaceutical, Inc., F. Hoffman-LaRoche Ltd. (through Spark Therapeutics), Spur Therapeutics Limited, Exegenesis Bio Co., 4D Molecular Therapeutics, Inc., and other gene therapy companies.
• Nuclease and base editing technologies: Caribou Biosciences, Inc., CRISPR Therapeutics AG, Editas Medicine, Inc., Intellia Therapeutics, Inc., Beam Therapeutics (CRISPR/Cas editing system), Cellectis S.A. (TALE nucleases and meganucleases), Precision BioSciences, Inc. (meganucleases), and other gene editing companies.
• Antisense therapeutics and RNA interference technology: Alnylam Pharmaceuticals, Inc., Ionis Pharmaceuticals, Inc., Moderna, Inc., Regulus Therapeutics Inc., Voyager Therapeutics, Inc., Wave Life Sciences, Inc., and other companies.
• Small molecules: Biogen, Inc., Pfizer Inc., Vertex Pharmaceuticals, Inc., and other companies.
• AAV capsid technologies: 4D Molecular Therapeutics, Affinia Therapeutics Inc., Capsida Biotherapeutics, Dyno Therapeutics, Inc., StrideBio, Inc., Voyager Therapeutics, Inc., and other companies.

Emerging Competitive Threats: The company faces competition from new entrants, disruptive technologies, and alternative solutions in the rapidly evolving genomic medicine field.

Competitive Response Strategy: SANGAMO THERAPEUTICS, INC. aims to compete by developing safe, efficacious, and commercially attractive proprietary products; securing access to gene transfer technology; obtaining regulatory approvals and reimbursement; attracting and retaining qualified scientific and product development personnel; forming strategic partnerships; protecting intellectual property; and developing products that are first to market, technologically superior, or lower cost.

Risk Assessment Framework

Strategic & Market Risks

Market Dynamics:

• Novel Technology Risk: The company's product candidates are based on novel genomic medicine technologies, leading to an unclear and potentially lengthy/expensive regulatory approval process. Public perception and increased regulatory scrutiny of genetically modified products could damage public acceptance and affect business operations.
• Competition: The biotechnology and genomic medicine fields are highly competitive, with numerous companies developing rival technologies and products that may be superior or commercialized more quickly.
• Product Acceptance: Even with regulatory approval, products may not gain market acceptance among physicians, patients, healthcare payors, and the medical community.
• Reimbursement Uncertainty: Significant uncertainty exists regarding the pricing structure, coverage, and adequate reimbursement for novel, potentially one-time, treatments. Government authorities and third-party payors are increasingly attempting to limit or regulate the price of medical products and services.
• Regulatory Changes: Disruptions at the FDA (e.g., workforce reductions, inadequate funding) or changes in FDA policies/regulations could delay or prevent approvals. Proposed EU pharmaceutical legislation (Pharma Package) may reduce baseline market protection periods and reshape orphan product incentives.

Operational & Execution Risks

Supply Chain Vulnerabilities:

• Supplier Dependency: Reliance on single suppliers for certain materials and key components creates a risk of significant delays if supply is interrupted.
• Manufacturing Complexity: The manufacture, storage, and transport of product candidates are complex, expensive, highly regulated (cGMP compliance), and risky, potentially hampering commercial viability.
• Third-Party Manufacturing Reliance: Substantial reliance on Contract Manufacturing Organizations (CMOs) for preclinical and clinical supply. Failure of CMOs to perform adequately or comply with regulations could jeopardize clinical trials and increase costs.

Internal Operations:

• Early Stage Programs: Core preclinical neurology programs are in early stages, and difficulties in advancing product candidates from research to preclinical and clinical development may be encountered.
• Resource Allocation: Risk of inefficient allocation of financial and human resources, potentially leading to missed opportunities for more profitable or successful programs.
• Employee Misconduct: Exposure to the risk of fraud or other misconduct by employees and contractors, including noncompliance with regulatory standards, which could lead to significant liability and reputational harm.
• Talent Management: Difficulties in hiring, integrating, and retaining qualified skilled employees due to intense competition in the biotechnology industry and past workforce reductions. Loss of key personnel could impede research, development, and regulatory efforts.
• Facility Risks: Operations are susceptible to natural disasters, catastrophic events, or other disruptions outside of the company's control, which could severely disrupt operations.

Financial & Regulatory Risks

Market & Financial Risks:

• Going Concern Doubt: There is substantial doubt about SANGAMO THERAPEUTICS, INC.'s ability to continue as a going concern due to a history of significant operating losses, negative operating cash flows, negative working capital, and dependence on substantial additional financing.
• Funding Dependency: The ability to fund operations and advance product candidates is wholly dependent on securing collaboration partners or additional capital, which may not be available on acceptable terms or at all.
• Dilution: Future sales and issuances of equity securities would result in substantial dilution to existing stockholders.
• Impairment Charges: The company has recorded significant impairment charges on its long-lived assets and may be required to record additional charges in the future.
• Net Operating Loss Limitations: The ability to use net operating loss carryforwards to offset future taxable income may be subject to substantial annual limitations due to ownership changes and state provisions.
• Stock Price Volatility: The company's stock price has been and will likely continue to be volatile, influenced by clinical trial results, market valuations, economic conditions, and public perception of the biotechnology sector.
• Delisting Risk: SANGAMO THERAPEUTICS, INC. currently does not meet Nasdaq Capital Market listing standards and does not expect to regain compliance by April 27, 2026, which could lead to delisting and substantially impair its ability to access capital markets.

Regulatory & Compliance Risks:

• Companion Diagnostic Approval: Failure to successfully obtain regulatory approval for the Fabry companion diagnostic could prevent approval of the BLA for isaralgagene civaparvovec.
• Post-Approval Scrutiny: Even if regulatory approval is obtained, products will remain subject to rigorous regulatory scrutiny, including potential restrictions on use, post-approval studies, and possible withdrawal of approval.
• Healthcare Laws & Regulations: Relationships with healthcare providers, customers, and third-party payors are subject to applicable anti-kickback, fraud and abuse, privacy, data security, and other healthcare laws and regulations. Non-compliance could result in regulatory investigations, litigation, and substantial fines.
• Privacy & Cybersecurity: Increasing dependence on information technology systems and the handling of large amounts of sensitive information expose the company to cybersecurity threats and evolving privacy regulations (e.g., EU General Data Protection Regulation, California Consumer Privacy Act). Security incidents could lead to regulatory actions, litigation, fines, and operational disruptions.

Geopolitical & External Risks

Geopolitical Exposure:

• International Trade Policies: International trade policies, including tariffs, sanctions, and trade barriers, may adversely affect the business by increasing research and development expenses, supply chain complexity, and operational risks.
• Global Economic Conditions: Unfavorable global economic conditions, including political instability, conflicts (e.g., Middle East, Russia-Ukraine), inflation, fluctuations in interest rates, and potential bank failures, could negatively impact operations and the ability to raise capital.

Innovation & Technology Leadership

Research & Development Focus: Core Technology Areas:

• Zinc Finger Platform: SANGAMO THERAPEUTICS, INC. is a leader in zinc finger proteins (ZFPs), naturally occurring DNA-binding proteins engineered to regulate gene expression. This platform enables the development of zinc finger repressors (ZFRs) to down-regulate target genes (e.g., SCN9A for neuropathic pain, PRNP for prion disease) and zinc finger activators (ZFAs) to increase gene expression. The platform also supports zinc finger nucleases (ZFNs) for gene knockout and compact ZF-base editors for precise single-base DNA changes.
• AAV Capsid Engineering Platform (SIFTER): A proprietary platform designed to engineer AAV capsids with improved central nervous system (CNS) transduction. This platform has identified STAC-BBB, a neurotropic AAV capsid variant capable of crossing the blood-brain barrier and mediating widespread CNS transduction and epigenetic repression. Other capsids like STAC-102 and STAC-103 have been identified for improved cerebrospinal fluid (CSF) administration.
• Modular Integrase Platform (MINT): A next-generation, protein-guided genome editing method that uses Bxb1 serine integrase to integrate large sequences of DNA into the genome, designed to avoid double-stranded DNA breaks. Preclinical data has demonstrated high-efficiency transgene integration in T cells.

Innovation Pipeline:

• Preclinical Neurology Programs: Includes ST-503 for small fiber neuropathy and ST-506 for prion disease, alongside partnered programs for tauopathies, amyotrophic lateral sclerosis (ALS), and other undisclosed neurology targets.
• Clinical Programs: Features isaralgagene civaparvovec for Fabry disease and giroctocogene fitelparvovec for hemophilia A.

Intellectual Property Portfolio:

• Patent Strategy: SANGAMO THERAPEUTICS, INC. actively files, obtains, maintains, licenses, and defends patents and patent applications to protect its technologies. The portfolio comprises approximately 110 patent families.
• Core IP: Covers the design, compositions, and uses of ZFPs, ZFNs, ZF-transcriptional factors, TALE proteins, and CRISPR/Cas editing systems, as well as viral vector delivery platforms, targeted gene therapies for various diseases, cell therapies, recombinases, integrases, and base editors.
• Patent Expiration: While some early zinc finger patents began expiring in 2015, newer patents provide protection for ZF technology (expected expiration dates ranging from 2029 to 2036), nuclease therapeutics (2031 to 2036), and capsid delivery technologies (2040 to 2045).
• Trade Secrets: The company relies on trade secret protection and confidentiality agreements for proprietary know-how not covered by patents.

Technology Partnerships:

• Strategic Alliances: Collaborations include Genentech, Inc., Astellas Gene Therapies, Inc., and Eli Lilly and Company for STAC-BBB capsid and/or ZFRs. Alexion Pharmaceuticals, Inc. for ALS and frontotemporal lobar degeneration, and Takeda Pharmaceutical Company Limited for Huntington’s Disease.
• Research Collaborations: Licenses technology for non-therapeutic applications with partners such as Corteva AgriScience (plant agriculture), Sigma-Aldrich Corporation (research reagents), and Open Monoclonal Technology, Inc. (now Ligand Pharmaceuticals Incorporated) (transgenic animals and cell-line engineering).

Leadership & Governance

Executive Leadership Team

Leadership Continuity: SANGAMO THERAPEUTICS, INC. has experienced difficulties in hiring, integrating, and retaining qualified skilled employees, particularly given the intense competition in the biotechnology industry and recent workforce reductions. The company has seen departures of senior executives in 2024 and 2025, and the employment of other executive vice presidents was terminated in connection with restructurings. All employees are "at will," and the company does not carry "key person" insurance on any employees.

Board Composition: The Board of Directors oversees the company's cybersecurity risk management as part of its general oversight function, with the Audit Committee specifically responsible for overseeing cybersecurity risk management processes.

Human Capital Strategy

Workforce Composition:

• Total Employees: As of March 27, 2026, SANGAMO THERAPEUTICS, INC. had 142 full-time employees.
• Geographic Distribution: 140 employees are located in the United States (primarily in the San Francisco Bay Area), and 2 are in the United Kingdom.
• Skill Mix: 57 employees are engaged in research and development, 43 in technical operations and manufacturing, and 42 in general and administrative activities.
• Growth Trends: The company has undergone significant workforce reductions, including approximately 272 roles eliminated in the April 2023 and November 2023 Restructurings, and 93 roles eliminated in the France Restructuring. The company is currently operating with a substantially reduced number of employees.

Talent Management: Acquisition & Retention:

• Hiring Strategy: The company competes in a highly competitive biotechnology industry for skilled individuals with experience in genomic medicines.
• Employee Value Proposition: SANGAMO THERAPEUTICS, INC. offers a competitive total rewards package, including at or above-market pay, comprehensive healthcare benefits, generous paid time off, family leave, flexible work schedules, retirement/pension contributions, mental health benefits, and equity ownership through stock option grants and restricted stock units. U.S. employees can also participate in an employee stock purchase plan.

Diversity & Development:

• Culture & Engagement: The company's core values emphasize "Doing what’s right for patients," "Succeeding through teamwork," "Innovating through smart decisions," and "Fostering belonging," with a commitment to nurturing diverse and inclusive environments.

Environmental & Social Impact

Environmental Commitments:

• Regulatory Compliance: SANGAMO THERAPEUTICS, INC. is subject to U.S. federal and state laws regarding safe working conditions, environmental protection, and hazardous substances. The company believes it is in material compliance with applicable environmental laws and regulations.